Shexiang Baoxin Pills as an Adjuvant Treatment for Chronic Heart Failure: A System Review and Meta-Analysis.
Shexiang Baoxin Pills as an Adjuvant Treatment for Chronic Heart Failure: A System Review and Meta-Analysis.
复制标题
麝香保心丸辅助治疗慢性心力衰竭：系统回顾与荟萃分析
DOI：
10.1155/2018/6949348
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Xie Q
中科院分区：
文献类型：
--
作者：
Dong T;Wang J;Ma X;Ma R;Wen J;Chen N;Xie Q
麝香保心丸是一种治疗慢性心力衰竭的传统中药。因此，系统评价SXBXP作为慢性心力衰竭辅助治疗的有效性和安全性至关重要。 检索了7个英文和中文电子数据库（PubMed、Embase、科克伦图书馆、CBM、万方、VMIS和CNKI），检索时间从开始到2017年7月。使用科克伦偏倚风险工具评价合格研究的方法学质量。由Review Manager 5.3进行荟萃分析。 本综述共纳入27项RCT，2637例受试者。在总有效率方面，参仙补虚方联合常规治疗组较常规治疗组疗效显著（OR，3.88; 95%CI，2.87，5.26; P < 0.00001），B型利钠肽（BNP）（MD = −66.95; 95% CI，−108.57，−25.34; P = 0.002），N末端脑钠肽前体（NT-ProBNP）（MD = −0.15; 95% CI，−0.21，−0.09; P < 0.00001），6分钟步行距离（6-MWD）（MD = 38.57; 95%CI，28.47，48.67; P < 0.00001），心输出量（CO）（MD = 0.84; 95% CI，0.68，0.99; P < 0.00001）和每搏输出量（SV）（MD = 7.43; 95% CI，4.42，10.44，P < 0.00001）。合并亚组分析显示，SXBXP加常规治疗组与单纯常规治疗组的近期疗效有显著性差异（OR = 3.51，95%CI，2.28，5.40; P < 0.00001），治疗中期（OR = 5.01; 95% CI，2.61，9.60; P < 0.00001），长期病程（OR = 3.77; 95% CI，2.13，6.67; P < 0.00001）。这些RCT中未提及严重不良事件或反应。 提示参仙补虚片作为辅助治疗CHF有明显疗效。然而，由于本研究中样本量小，研究质量普遍较低，因此需要更严格和设计良好的RCT来证实这些发现。
Shexiang Baoxin pills (SXBXP), as a Traditional Chinese Medicine, are widely used for chronic heart failure in China. It is essential to systematically assess the efficacy and safety of SXBXP as an adjuvant treatment for chronic heart failure. Seven English and Chinese electronic databases (PubMed, Embase, Cochrane Library, CBM, Wanfang, VMIS, and CNKI) were searched from inception to July 2017. The Cochrane Risk of Bias tool was used to evaluate the methodological quality of eligible studies. Meta-analysis was performed by Review Manager 5.3. A total of 27 RCTs with 2637 participants were included in this review. Compared to conventional treatment, SXBXP combined with conventional treatment showed potent efficacy when it came to the total efficacy rate (OR, 3.88; 95% CI, 2.87, 5.26; P < 0.00001), B-type natriuretic peptide (BNP) (MD = −66.95; 95% CI, −108.57, −25.34; P = 0.002), N-terminal pro-brain natriuretic peptide (NT-ProBNP) (MD = −0.15; 95% CI, −0.21, −0.09; P < 0.00001), six-minute walking distance (6-MWD) (MD = 38.57; 95% CI, 28.47, 48.67; P < 0.00001), cardiac output (CO) (MD = 0.84; 95% CI, 0.68, 0.99; P < 0.00001), and Stroke Volume (SV) (MD = 7.43; 95% CI, 4.42, 10.44, P < 0.00001). The pooled subgroup analysis indicated that there was a significant difference between SXBXP plus conventional treatment and conventional treatment alone in short term course (OR = 3.51; 95% CI, 2.28, 5.40; P < 0.00001), in middle period of treatment (OR = 5.01; 95% CI, 2.61, 9.60; P < 0.00001), and in long-term course (OR = 3.77; 95% CI, 2.13, 6.67; P < 0.00001). No serious adverse events or reactions were mentioned in these RCTs. As an adjuvant drug, this study suggested that SXBXP provide an obvious efficacy for the treatment of CHF. However, due to small samples and generally low quality studies being applied in this study, more rigorous and well-designed RCTs are needed to confirm these findings.
登录
查看更多内容
DOI：
10.1161/hhf.0b013e318291329a
发表时间：
2013-05
期刊：
Circulation. Heart failure
影响因子：
--
作者：
Heidenreich PA;Albert NM;Allen LA;Bluemke DA;Butler J;Fonarow GC;Ikonomidis JS;Khavjou O;Konstam MA;Maddox TM;Nichol G;Pham M;Piña IL;Trogdon JG;American Heart Association Advocacy Coordinating Committee;Council on Arteriosclerosis, Thrombosis and Vascular Biology;Council on Cardiovascular Radiology and Intervention;Council on Clinical Cardiology;Council on Epidemiology and Prevention;Stroke Council
通讯作者：
Stroke Council
影响因子：
8.6
作者：
Berg, Daniela;Postuma, Ronald B.;Bloem, Bastiaan;Chan, Piu;Dubois, Bruno;Gasser, Thomas;Goetz, Christopher G.;Halliday, Glenda M.;Hardy, John;Lang, Anthony E.;Litvan, Irene;Marek, Kenneth;Obeso, Jose;Oertel, Wolfgang;Olanow, C. Warren;Poewe, Werner;Stern, Matthew;Deuschl, Guenther
通讯作者：
Deuschl, Guenther
影响因子：
5
作者：
Lok, Dirk J.;Lok, Sjoukje I.;van der Meer, Peter
通讯作者：
van der Meer, Peter
DOI：
10.3724/sp.j.1008.2013.00037
发表时间：
2013-01-01
影响因子：
--
作者：
Ding Ru, Ding Ru;Gui YanPing, Gui YanPing;Wu, Z. G.
通讯作者：
Wu, Z. G.
灵敏快速液相色谱-串联质谱法研究大鼠单次和多次口服麝香保心丸后五种人参皂苷的药代动力学
影响因子：
1.8
作者：
Peng, Chengcheng;Yang, Yongge;Zhang, Weidong
通讯作者：
Zhang, Weidong